SmartNuclide Overview
- Year Founded
-
2015
- Status
-
Private
- Latest Deal Type
-
Series D
- Investors
-
24
SmartNuclide General Information
Description
Developer of radiopharmaceuticals designed for tumor imaging and therapy. The company utilizes radionuclide-protein conjugation and single-domain antibody platforms, providing recombinant human thyrotropin, pd-l1 diagnostic imaging agents, cd8+ t cells imaging agents, targeted radioligand therapies, radioisotope-targeted imaging agents, and radioactive therapeutic agents, enabling healthcare providers to access precise diagnostic and therapeutic options for oncology patients.
Contact Information
Website
www.smartnucl.comCorporate Office
- A4-201/202, 206, Biopharmaceutical Industrial Park
- Number 218 Xinghu Street
- Suzhou, Jiangsu 215000
- China
Corporate Office
- A4-201/202, 206, Biopharmaceutical Industrial Park
- Number 218 Xinghu Street
- Suzhou, Jiangsu 215000
- China
SmartNuclide Timeline
SmartNuclide Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series D) | 14-Sep-2026 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series C1) | 09-Apr-2024 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series C) | 05-Jul-2021 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B) | 09-Apr-2020 | Completed | Generating Revenue | |||
| 3. Secondary Transaction - Private | 12-Nov-2018 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 01-Jan-2017 | Completed | Generating Revenue | |||
| 1. Seed Round | 21-Mar-2016 | Completed | Startup |
SmartNuclide Investors (24)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| KGW Investment | Growth/Expansion | Minority | ||
| Star Capital Investment Management | Growth/Expansion | Minority | ||
| Beijing Ruihe Xinyi Investment | Growth/Expansion | Minority | ||
| Guangzhou Jiansu Private Equity Fund Management | Growth/Expansion | Minority | ||
| Healthib Capital | PE/Buyout | Minority |
SmartNuclide FAQs
-
When was SmartNuclide founded?
SmartNuclide was founded in 2015.
-
Where is SmartNuclide headquartered?
SmartNuclide is headquartered in Suzhou, China.
-
What industry is SmartNuclide in?
SmartNuclide’s primary industry is Drug Discovery.
-
Is SmartNuclide a private or public company?
SmartNuclide is a Private company.
-
What is SmartNuclide’s current revenue?
The current revenue for SmartNuclide is .
-
How much funding has SmartNuclide raised over time?
SmartNuclide has raised $43.6M.
-
Who are SmartNuclide’s investors?
KGW Investment, Star Capital Investment Management, Beijing Ruihe Xinyi Investment, Guangzhou Jiansu Private Equity Fund Management, and Healthib Capital are 5 of 24 investors who have invested in SmartNuclide.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process